Ranked #4,308 of 8,699 institutional investors
Atle Fund Management AB
Stockholm, V7
$385M
US stock portfolio at live prices · today −$3.2M (−0.81%)
Market closed. Prices as of Nov 20, 9:11 AM ET
- Value at quarter end (Q3 2026)
- $373M
- Change from Q2 2026
- +$1.7M (+0.45%)
- Positions
- 37 · 4 new, 4 sold out
- Filed
- Nov 12, 2026
Not counted in the ranking: none$12.9M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesLLY 11.0%ABBV 6.72%JNJ 6.34%TMO 6.16%MRK 5.83%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| LLY Eli Lilly and Company | 31,202 | $42.2M | 11.0% | Added +5% |
| ABBV AbbVie Inc. | 91,294 | $25.9M | 6.72% | Added +42% |
| JNJ Johnson & Johnson | 91,387 | $24.4M | 6.34% | Added +7% |
| TMO Thermo Fisher Scientific Inc. | 34,410 | $23.7M | 6.16% | Added +24% |
| MRK Merck & Co., Inc. | 168,987 | $22.4M | 5.83% | Reduced −11% |
| BIIB Biogen Inc. | 70,955 | $17.5M | 4.55% | Added +13% |
| VRTX Vertex Pharmaceuticals Incorporated | 28,157 | $14.7M | 3.81% | Added +47% |
| ONC BeOne Medicines AG | 35,679 | $14.3M | 3.70% | Added +1% |
| BBIO BridgeBio Pharma, Inc. | 163,697 | $12.8M | 3.32% | Added +31% |
| INSM Insmed Incorporated | 87,469 | $12.6M | 3.28% | Added +50% |
| COR Cencora, Inc. | 36,107 | $12.3M | 3.20% | Added +16% |
| EW Edwards Lifesciences Corporation | 109,647 | $11.4M | 2.96% | Added +6% |
| CVS CVS Health Corporation | 139,311 | $11.2M | 2.90% | Reduced −5% |
| SYK Stryker Corporation | 34,296 | $10.7M | 2.79% | Added +13% |
| RVMD Revolution Medicines, Inc. | 66,113 | $10.5M | 2.74% | Reduced −10% |
| ISRG Intuitive Surgical, Inc. | 25,648 | $10.4M | 2.71% | Added +4% |
| INCY Incyte Corporation | 77,377 | $9.0M | 2.33% | Added +36% |
| KRYS Krystal Biotech, Inc. | 28,074 | $8.9M | 2.30% | Added +17% |
| CAH Cardinal Health, Inc. | 26,735 | $7.3M | 1.89% | Added +13% |
| DXCM DexCom, Inc. | 89,251 | $7.2M | 1.86% | Added +24% |
| GILD Gilead Sciences, Inc. | 40,461 | $6.7M | 1.75% | Reduced −12% |
| MIRM Mirum Pharmaceuticals, Inc. | 70,071 | $6.7M | 1.74% | Reduced −30% |
| NBIX Neurocrine Biosciences, Inc. | 38,611 | $6.0M | 1.57% | Reduced −47% |
| BSX Boston Scientific Corporation | 130,622 | $5.6M | 1.46% | Reduced −11% |
| IRTC iRhythm Holdings, Inc. | 54,102 | $5.1M | 1.32% | Unchanged |
| SYRE Spyre Therapeutics, Inc. | 44,243 | $4.3M | 1.12% | Reduced −22% |
| ORKA Oruka Therapeutics, Inc. | 43,180 | $4.2M | 1.09% | Reduced −21% |
| TNGX Tango Therapeutics, Inc. | 184,394 | $4.2M | 1.09% | Reduced −7% |
| ABVX ABIVAX Société Anonyme | 46,452 | $3.7M | 0.97% | Reduced −20% |
| IRON Disc Medicine, Inc. | 43,682 | $3.3M | 0.86% | Unchanged |
| IDYA IDEAYA Biosciences, Inc. | 93,550 | $2.4M | 0.64% | Reduced −1% |
| PVLA Palvella Therapeutics, Inc. | 14,924 | $2.2M | 0.57% | New |
| CMPS COMPASS Pathways plc | 243,506 | $2.1M | 0.55% | New |
| SMMT Summit Therapeutics Inc. | 184,687 | $2.0M | 0.51% | New |
| CELC Celcuity Inc. | 29,893 | $1.7M | 0.44% | Reduced −10% |
| MANE Veradermics Inc | 10,106 | $1.3M | 0.33% | New |
| PYXS Pyxis Oncology, Inc. | 663,772 | $1.1M | 0.29% | Reduced −31% |